CAR-T Cell Therapy for Desensitization in Kidney Transplantation

Exclusion Criteria

• •1. Subjects with indwelling catheters as primary access for hemodialysis
• •2. Previous solid organ (except kidney) or bone marrow transplant
• •3. BMI ≥35 kg/m\^2
• •4. Subjects who have preserved or oliguric urine output \> 100 cc/day with history of recurrent UTI (2 in 6 months or 3 in 1 year, see study definitions)
• •5. Subjects described in exclusion #4 with structural disease such as polycystic kidney disease, obstructive uropathy with nephrolithiasis or those otherwise at higher risk of urinary tract infections. Anuric subjects with structural kidney disease are not excluded
• •6. Known active current or history of invasive fungal infection; any non-tuberculous mycobacterial infection that has been active or has required therapy within the last year. Any infection requiring hospitalization and IV antibiotics within 4 weeks of screening or PO antibiotics within 2 weeks
• •7. History of HIV, chronic HBV, or chronic HCV, regardless of treatment
• •8. Negative CMV serology
• •9. Detectible viral load HBV, HCV, CMV, EBV, or BK by PCR
• •10. Any B cell depleting or monoclonal antibody therapy within 6 months prior to enrollment
• •11. Receiving ongoing immunosuppression including corticosteroids, intravenous immunoglobulin, cyclophosphamide, tacrolimus, mycophenolic acid, or azathioprine from 90 days prior to study entry
• •12. Active auto-immune disease, including connective tissue disease, uveitis, sarcoidosis, inflammatory bowel disease, or multiple sclerosis, or have a history of severe (as judged by the investigator) autoimmune disease requiring prolonged immunosuppressive therapy, except for renal-limited autoimmune conditions without risk for systemic manifestations (e.g. IgA nephropathy)
• •13. Any chronic illness requiring uninterrupted anti-coagulation or anti-platelet therapy
• •14. History of cirrhosis or severe liver disease, including abnormal liver profile (aspartate aminotransferase \[AST\], alanine aminotransferases \[ALT\] or total bilirubin \> 3 times upper limit of normal at screening (except for patients in whom hyperbilirubinemia is attributed to Gilbert's syndrome)
• •15. History of sickle cell disease, or systemic amyloidosis
• •16. Cardiac clearance for transplant \> 6 months old and/or any of the following: NYHA Class III or IV heart failure, unstable angina, left ventricular ejection fraction \< 40%, a history of recent (within 6 months) myocardial infarction or implantable cardioverter/ defibrillators and/or biventricular pacing.
• •17. Moderate-severe pulmonary function abnormality, defined as resting oxygen saturation \<92% on room air or FEV1, TLC, or DLCO (after correction for hemoglobin) \<50% of predicted values
• •18. Patients who have received any live vaccine within 30 days of planned leukapheresis
• •19. Treatment with any investigational agent within 4 weeks (or 5 half-lives of investigational drug, whichever is longer) of screening
• •20. Pregnant, currently breastfeeding, or planning to become pregnant during the primary or post-transplant follow up of the study.
• •21. Past or current social or medical problems; or findings from physical examination or laboratory testing that are not listed above, which in the opinion of investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study
• •Lymphodepleting Chemotherapy Eligibility:
• •Study entry eligibility must be re-assessed prior to starting lymphodepletion. In addition, subjects must undergo respiratory viral testing on nasal or nasopharyngeal swabs (per institutional practice) for SARS-CoV-2 and influenza within 7 days prior to the first planned lymphodepletion chemotherapy.
• •1. If the subject is positive for influenza, Tamiflu® or equivalent should be administered per package insert. The subject must complete treatment and symptoms must be improving and either resolved or nearly resolved in the judgment of the treating investigator prior to receiving lymphodepleting chemotherapy and CAR T cells. Repeat influenza testing is not required prior to initiating lymphodepleting chemotherapy and CAR T cell infusion.
• •2. If the subject tests positive for SARS-CoV-2, the subject will be managed per institutional practice. Subject will be eligible to initiate lymphodepleting chemotherapy and CAR T cell infusion once cleared from requirement for isolation according to institutional and/or CDC guidance.
• •3. If testing is positive for another respiratory virus (e.g., as part of a multiplex respiratory pathogen panel in the course of testing for influenza or SARS-CoV-2), the lymphodepleting chemotherapy and CAR T cell infusion will be delayed for at least 7 days to be sure clinical symptoms of a viral infection do not develop. If clinical symptoms develop, the lymphodepleting chemotherapy and CAR T cell infusion will be delayed until resolution of these symptoms.
• •CAR T Cell Infusion Eligibility:
• •The criteria below will be assessed by the investigator following lymphodepleting chemotherapy and before administration of CAR T cells. Subjects who do not satisfy these criteria may have CAR T cell infusion delayed until such time as criteria are satisfied. Subjects who receive lymphodepleting chemotherapy but in whom CAR T cell infusion is delayed \>4 weeks after the first day of lymphodepleting chemotherapy will receive a second cycle of lymphodepleting chemotherapy prior to CAR T cell infusion. For subjects receiving fludarabine, a second cycle of cyclophosphamide can be administered, but fludarabine will not be repeated.
• •1. Subjects must not have developed deterioration in performance status or overall clinical condition or new laboratory abnormalities that would, in the opinion of the treating investigator, render it unsafe to proceed with CAR T cell infusion. The following are specific conditions that warrant delaying CAR T cell infusion:
• •1. Requirement for supplemental oxygen to maintain peripheral oxygen saturation ≥95%.
• •2. Presence of clinically significant radiographic abnormalities on chest x-ray. Chest x-ray is not required to evaluate for radiographic abnormalities in the absence of suggestive symptoms or exam findings.
• •3. New cardiac arrhythmia not controlled with medical management. EKG is not required to evaluate for arrhythmia in the absence of suggestive symptoms or exam findings.
• •4. Hypotension requiring vasopressor support.
• •5. Active infection: Diagnostic test results indicating new bacterial, fungal, or viral infection within prior 48 hours.
• •2. Subjects must have adhered to restrictions on pre-infusion therapy.